Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Halozyme ( (HALO) ) has provided an announcement.
On February 11, 2025, Connie L. Matsui, a long-serving member of Halozyme Therapeutics’ Board of Directors, announced her decision not to stand for reelection at the 2025 annual stockholders’ meeting. Her departure is amicable and not due to any disagreements with the company’s operations or strategies, and her contribution over nearly 18 years has been appreciated by the management and board.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of products that enhance the delivery of injectable drugs.
YTD Price Performance: 21.04%
Average Trading Volume: 1,619,852
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $7.39B
See more data about HALO stock on TipRanks’ Stock Analysis page.
